Alkermes drug gets fast-track status; FDA's Woodcock staying put; Opioid-induced constipation market taking off;

@FiercePharma: Top 10 Drugmakers in Emerging Markets--our latest special report. Feature | Follow @FiercePharma

@EricPFierce:  spent €39B on emerging markets deals over 4 years. It has 40 manufacturing sites in these countries. More | Follow @EricPFierce

@CarlyHFierce: Vivus and Auxilium sign marketing deal for ED drug Stendra in the U.S. and Canada. Article | Release | Follow @CarlyHFierce

> Alkermes ($ALKS) says the FDA has granted fast-track status for its experimental medicine to combat depression, intended for patients who don't respond to standard therapies. Report

> The U.K.'s Association of the British Pharmaceutical Industry (ABPI) is taking a look at its code of practice for drugmakers in the U.K. and expects to recommend changes for an update slated for January 2015. Story

> Janet Woodcock, director of the the FDA's Center for Drug Evaluation and Research (CDER), sent a memo to agency staff saying she has no plans to retire after a Reuters story pointed out she was nearing an age when she might. Story | More from FierceBiotech

> GlaxoSmithKline ($GSK) has opened what it refers to as the Human Performance Lab for researching how the body is fueled, boosting health and understanding keys to longevity. Story

> The FDA says it is investigating an increasing frequency of reports of serious and life-threatening blood clots and severe narrowing of blood vessels (arteries and veins) of patients taking Ariad's ($ARIA) leukemia chemotherapy drug Iclusig (ponatinib). Release

Medical Device News

@FierceMedDev: Biotronik unveils next-gen MRI-safe ICDs. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: Quest Diagnostics warns that its Q3 numbers won't be meeting expectations. Blame reimbursement pressures, etc. More | Follow @MarkHFierce

@MichaelGFierce: Check out this week's FierceDrugDelivery newsletter! RNAi roundup & stem cell drug delivery action. Report | Follow @MichaelGFierce

> St. Jude Medical CEO knocks rival and regulatory climate, but also offers optimism. More

> Gov't shutdown halts FCC's wireless med tech certification. Item

> Bipartisan backing of device tax repeal threatened by gov't funding fight. Story

> German-U.S. team test intestinal tube implant to treat obesity. Article

Biotech News

@FierceBiotech: Still popular: 10 top drugs in biopharma's late-stage pipeline. Feature | Follow @FierceBiotech

@JohnCFierce: Osiris exits stem cell business, sells unit to Mesoblast in $100M deal. News | Follow @JohnCFierce

@DamianFierce: In case you missed it, some thoughts on why med tech companies aren't riding the biotech IPO wave. Editor's Corner | Follow @DamianFierce

@EmilyMFierce: Compound halts neurodegeneration in mice. Story from FierceBiotech Research | Follow @EmilyMFierce

> Celladon, Xencor bid for $155M in red-hot IPO market. Story

> Researchers hit Alzheimer's 'turning point' with new target. Article

> MacroGenics shares soar on glittering $80M IPO debut. Report

And Finally... GlobalData claims the opioid-induced constipation (OIC) global market will post nearly a 32% compound annual growth rate and hit $1.98 billion by 2017, up from just $144.42 million in 2012. Release

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.